A5028142705- Bone health and osteoporosis research
- Bone health and treatments
- Parathyroid Disorders and Treatments
- Hip and Femur Fractures
- Bone and Joint Diseases
- Vitamin D Research Studies
- Bone Metabolism and Diseases
- Neuroendocrine Tumor Research Advances
- Histiocytic Disorders and Treatments
- Orthopaedic implants and arthroplasty
- Immunotherapy and Immune Responses
- Magnesium in Health and Disease
- Salivary Gland Disorders and Functions
- Genetic Syndromes and Imprinting
- Adrenal Hormones and Disorders
- Growth Hormone and Insulin-like Growth Factors
- Diabetes and associated disorders
- Hip disorders and treatments
- Medical Imaging and Pathology Studies
- Alkaline Phosphatase Research Studies
- Parvovirus B19 Infection Studies
- Thyroid and Parathyroid Surgery
- Medical Imaging and Analysis
- Balance, Gait, and Falls Prevention
- Parkinson's Disease and Spinal Disorders
University of Sheffield
2019-2025
Sheffield Teaching Hospitals NHS Foundation Trust
2022-2024
Northern General Hospital
2023
Versus Arthritis
2022
Academy of Athens
2014
National and Kapodistrian University of Athens
2012-2014
Bone turnover markers (BTMs) are used widely, in both research and clinical practice. In the last 20 years, much experience has been gained measurement interpretation of these markers, which include commonly bone formation (bone alkaline phosphatase, osteocalcin, procollagen I N-propeptide); resorption (serum C-telopeptides type collagen, urinary N-telopeptides tartrate-resistant acid phosphatase 5b). BTMs usually measured by enzyme-linked immunosorbent assay or automated immunoassay....
Abstract Context Normocalcemic hyperparathyroidism (NPHPT) is characterized by persistently normal calcium levels and elevated parathyroid hormone (PTH) values, after excluding other causes of secondary hyperparathyroidism. The prevalence the disease varies greatly data on natural history this are sparse inconclusive. Objectives objectives study to describe NPHPT its in a referral population compare variability serum with group patients primary (PHPT). Design A retrospective was conducted...
Abstract Some osteoporosis drug trials have suggested that treatment is more effective in those with low BMD measured by DXA. This study used data from a large set of randomized controlled (RCTs) to determine whether the anti-fracture efficacy treatments differs according baseline BMD. We individual patient 25 RCTs (103 086 subjects) medications collected as part FNIH-ASBMR SABRE project. Participants were stratified into FN T-score subgroups (≤−2.5, > −2.5). Cox proportional hazard...
Purpose of review The assessment fracture risk is playing an ever-increasing role in osteoporosis clinical management and informing international guidelines for osteoporosis. FRAX, a calculator that provides individualized 10-year probabilities hip major osteoporotic fracture, has been widely used since 2008. In this review, we recap the development limitations intervention thresholds absolute risk. Recent findings There increasing awareness disparities inequities setting simple use prior or...
Abstract Purpose To describe diagnostic approaches and management strategies for patients with primary hyperparathyroidism (PHPT) recent fracture in England. Methods We developed a survey based on patient at high risk new diagnosis of probable PHPT. The was circulated among 50 secondary care professionals identified by the Society Endocrinology Calcium Bone special interest group. Descriptive statistics, combinatorial, thematic analyses were employed. Results In fracture, 54% respondents...
Primary hyperparathyroidism is a common condition and results in hypercalcaemia, especially older women. Thus, it critical to obtain robust estimate for the upper limit of reference interval albumin-adjusted serum calcium general population. The current use UK (Pathology Harmony range, 2.20 2.60 mmol/L) was based on consensus.
In Sheffield (UK), we introduced the PINP monitoring algorithm for management of osteoporosis treatment delivered in primary care. Our aims were to evaluate whether this was associated with better outcomes and cost-effective compared standard Inclusion criteria referral from GPs, BMD scans performed between 2012 2013 a report advising initiation oral bisphosphonate monitoring. 906 patients identified retrospectively divided into Group A (intention monitor, baseline PINP, n = 588) B (no...
Abstract There is a common belief that antiosteoporosis medications are less effective in older adults. This study used data from randomized controlled trials (RCTs) to determine whether the anti-fracture efficacy of treatments and their effects on BMD differ people ≥70 compared those <70 yr. We individual patient 23 RCTs osteoporosis collected as part FNIH-ASBMR SABRE project. assessed following fractures: radiographic vertebral, non-vertebral, hip, all clinical, fractures. Cox...
There is a strong association between total hip bone mineral density (THBMD) changes after 24 mo of treatment and reduced fracture risk. We examined whether in THBMD 12 18 are also associated with risk reduction. used individual patient data (n = 122 235 participants) from 22 randomized, placebo-controlled, double-blind trials osteoporosis medications. calculated the difference mean percent change (active-placebo) at 12, 18, using available for each trial. determined treatment-related...
To evaluate the prevalence of antibodies to 21-hydroxylase (anti-21[OH]), a marker autoimmune adrenal disease, in cohort patients with primary Sjögren's syndrome (SS) and investigate whether presence anti-21(OH) correlates clinical, serologic, salivary gland features disease.Sera from 63 consecutive SS, 32 thyroid disease (AITD), 20 healthy controls were obtained levels determined by radioimmunoassay. Clinical, histopathologic recorded, short Synacthen test was used assess function reserve....
Abstract Disclosure: T. Vilaca: None. M.T. Schini: A.R. Thompson: E. Vittinghoff: L. Lui: S.K. Ewing: D.C. Bauer: D.M. Black: M. Bouxsein: R. Eastell: Consulting Fee; Self; Immunodiagnostic Systems, CL Bio, CureTeQ, Biocon, Takeda, UCB. Grant Recipient; Alexion Pharmaceuticals, Inc., Osteolabs. Speaker; Pharmacosmos, Amgen Inc, Introduction: To date, trials of new anti-osteoporosis therapies have used fractures as primary endpoints. In the FNIH-ASBMR-SABRE project, we posited that...
Bisphosphonate treatment in adults with hypophosphatasia (HPP) may increase fracture risk. PLP is a useful marker biochemically differentiating HPP from osteoporosis adults. In order to identify elevated PLP, robust reference intervals are needed which calculated large, representative sample population.Complete data 9069 individuals (ages 20-80, 50.6% female) two years of the NHANES Survey (2007-2008 and 2009-2010) were investigated. Differences presence four factors; inflammation (CRP ≥5.0...